




## <sup>177</sup>Lu-EBRGD

### Targeting $\alpha_v\beta_3$ overexpressing tumors


In development for the treatment of Glioblastoma Multiforme (GBM) and Non-Small Cell Lung Cancer (NSCLC)

## PET/CT slice of a glioblastoma (GBM) patient




<sup>64</sup>Cu-EBRGD  
24 H post injection


1 H




8 H



12 H



24 H



### Challenges

- No effective treatment for GBM
- Limited number of NSCLC patients respond to immunotherapy
- NSCLC incidence 58/100k
- GBM incidence 5/100K

### Solution

<sup>64</sup>Cu and <sup>68</sup>Ga radiolabeled Evans Blue (EB) conjugates prolong circulation half-life and improve tumor targeting in  $\alpha_v\beta_3$ -expressing tumors, markedly improved over NOTA- or DOTA-conjugated c(RGDfK) therapeutics.

### Technology

Patent pending.

### Proof of Concept

Extensive preclinical and Phase I theranostic studies show good safety and efficacy.

### Next

- IND early 2021
- Phase I trials in 2021

### MTTI

Molecular Targeting Technologies, Inc. is a privately held biotechnology company focused on the development of novel prolonged targeted radiotherapeutics (PTR) for disease treatment.

Contact: [cpak@mtarget.com](mailto:cpak@mtarget.com)

More information: [www.mtarget.com](http://www.mtarget.com).